Artiva halts AlloNK development after safety events, insufficient response durability
Bitget2026/10/27 11:32- Artiva Biotherapeutics is discontinuing AlloNK development, including its planned Phase 3 trial, as longer-term clinical response durability fell below its threshold.
- Two trial participants died; one event was linked to likely fludarabine neurotoxicity, while the other was assessed as unrelated to study treatment.
- No additional patients will receive AlloNK in ongoing studies; safety monitoring will continue.
- The workforce will shrink approximately 94% to preserve capital while strategic alternatives, including a potential merger, asset sale or liquidation, are evaluated.
- Preliminary, unaudited cash, cash equivalents and investments totaled approximately $319.1 million as of September 30, 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Vodafone (VOD.US) Swings to Loss in First Half, German Operations Major Drag
Vodafone (VOD.US) released its financial results for the first half of fiscal year 2027.
AI gamble backfires! Data center project writedowns and weak tech stock positions drag down SoftBank (SFTBY.US) to a Q2 loss of $7.1 billion
SoftBank recorded its first net loss in nearly two years due to a $3.7 billion impairment loss arising from a U.S. data center project, coupled with mounting market concerns over the sustainability of artificial intelligence (AI) growth impacting the investment giant’s key holdings.
AI Cloud Sector Faces a Key Moment: CoreWeave (CRWV.US) Set to Announce Earnings, Wells Fargo Remains Bullish
CoreWeave (CRWV.US) will release its third-quarter financial report after the U.S. stock market closes on Tuesday. This is seen as a key test for the strength of the new AI cloud sector.
JPMorgan raises target prices for Target and Walmart
Crypto prices
More
